Purpose: We aimed to assess the subfoveal choroidal thickness (SFChT) and the effect of treatment with anti-vascular endothelial growth factor (anti-VEGF) agents on the SFChT in age-related macular degeneration (AMD) subtypes. Methods: We enrolled 128 eyes of 107 patients with neovascular AMD (60 women; 47 men; mean age, 73.6 ± 8.9 years), and prospectively evaluated the best-corrected visual acuity (BCVA) and SFChT at baseline and at 3, 6, and 12 months after treatment with anti-VEGF agents. Patients were assigned to the typical AMD, polypoidal choroidal vasculopathy (PCV), and retinal angiomatous proliferation (RAP) subgroups. Results: In total, 85 (66.4%), 31 (24.2%), and 12 (9.4%) eyes were assigned to the typical AMD, PCV, and RAP subgroups, respectively. The baseline mean BCVA was 0.75 ± 0.26, 0.72 ± 0.21, and 0.77 ± 0.24 logMAR in the typical AMD, PCV, and RAP subgroups, respectively (p = 0.774). The mean baseline SFChT was 203.20 ± 35.80, 271.80 ± 24.50, and 182.93 ± 31.31 µm, respectively (p < 0.001). Mean SFChT significantly decreased from baseline to 3, 6, and 12 months after treatment. The RAP subtype presented a significantly higher decrease in SFChT compared to the other subtypes (p = 0.01). The percentage reduction in SFChT was not significantly correlated with the number of injections (r = –0.02; p = 0.823). No association was observed between baseline SFChT and final visual acuity at 12 months (r = 0.0; p = 0.586). Conclusions: SFChT was greatest in eyes with PCV and least in eyes with RAP. The reduction in SFChT after treatment was greater in the RAP cases. The decrease in SFChT after 12 months of anti-VEGF treatment was not associated with the number of injections and there was no correlation between the baseline SFChT and visual acuity in all AMD subtypes.

Keywords:
Age-related macular degeneration, anti-VEGF treatment, Subfoveal choroidal thickness
1.
Klein R, Peto T, Bird A, et al: The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004; 137: 486–495.
2.
Nowak JZ: Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006; 58: 353–363.
3.
Yannuzzi LA, Ciardella A, Spaide RF, et al: The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 1997; 115: 478–485.
4.
Yannuzzi LA, Negrao S, Iida T, et al: Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001; 21: 416–434.
5.
Liakopoulos S, Ongchin S, Bansal A, et al: Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49: 5048–5054.
6.
Spaide RF, Koizumi H, Pozzoni MC: Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 2008; 146: 496–500.
7.
Ogasawara M, Maruko I, Sugano Y, et al: Retinal and choroidal thickness changes following intravitreal ranibizumab injection for exudative age-related macular degeneration. Nippon Ganka Gakkai Zasshi 2012; 116: 643–649.
8.
Maruko I, Iida T, Sugano Y, et al: Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2011; 151: 594–603.
9.
Maruko I, Iida T, Oyamada H, et al: Choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy in recurrent polypoidal choroidal vasculopathy. Am J Ophthalmol 2013; 156: 548–556.
10.
Koizumi H, Kano M, Yamamoto A, et al: Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol 2015; 159: 627–633.
11.
Yamazaki T, Koizumi H, Yamagishi T, et al: Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 2012; 119: 1621–1627.
12.
Ellabban AA, Tsujikawa A, Ogino K, et al: Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Clin Ophthalmol 2012; 6: 837–844.
13.
Coscas F, Puche N, Coscas G, et al: Comparison of macular choroidal thickness in adult onset foveomacular vitelliform dystrophy and age-related macular degeneration. Invest Ophthalmol Vis Sci 2014; 55: 64–69.
14.
Sohn EH, Khanna A, Tucker BA, et al: Structural and biochemical analyses of choroidal thickness in human donor eyes. Invest Ophthalmol Vis Sci 2014; 55: 1352–1360.
15.
Koizumi H, Yamagishi T, Yamazaki T, et al: Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 2011; 249: 1123–1128.
16.
Chung SE, Kang SW, Lee JH, et al: Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 2011; 118: 840–845.
17.
Yamazaki T, Koizumi H, Yamagishi T, et al: Subfoveal choroidal thickness in retinal angiomatous proliferation. Retina 2014; 34: 1316–1322.
18.
Kang HM, Kwon HJ, Yi JH, et al: Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Am J Ophthalmol 2014; 157: 1013–1021.
19.
Gharbiya M, Cruciani F, Mariotti C, et al: Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 2015; 31: 357–362.
20.
Ting D, Ng WY, Ng SR, Tan SP, et al: Choroidal thickness changes in age-related macular degeneration and polypoidal choroidal vasculopathy: a 12-month prospective study. Am J Ophthalmol 2016; 164: 128–134.
21.
Yun C, Oh J, Ahn J, et al: Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2016; 254: 1693.
22.
Koizumi H, Kano M, Yamamoto A., et al: Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration. Ophthalmology 2016; 123: 617–624.
23.
Kano M, Tetsuju S, Yukinori S, et al: Foveal structure during the induction phase of anti-vascular endothelial growth factor therapy for occult choroidal neovascularization in age related macular degeneration. Clin Ophthalmol 2015; 9: 2049–2056.
24.
Koh A, Lee WK, Chen LJ, et al: EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; 32: 1453–1464.
25.
Yannuzzi LA, Negrao S, Iida T, et al: Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001; 21: 416–434.
26.
Holladay JT: Proper method for calculating average visual acuity. J Refract Surg 1997; 13: 338–391.
27.
Grunwald JE, Hariprasad SM, DuPont J: Foveolar choroidal blood flow in age-related macular degeneration. Invest Ophthalmol Vis Sci 1998; 39: 385–390.
28.
Grossniklaus HE, Green WR: Choroidal neovascularization. Am J Ophthalmol 2004; 137: 496–503.
29.
Friedman E: A hemodynamic model of the pathogenesis of age-related macular degeneration. Am J Ophthalmol 1997; 124: 677–682.
30.
Pereira FB, Veloso CE, Kokame GT, et al: Characteristics of neovascular age-related macular degeneration in Brazilian patients. Ophthalmologica 2015; 234: 233–242.
31.
Maruko I, Iida T, Saito M, et al: Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007; 144: 15–22.
32.
Ciardella AP, Donsoff IM, Yannuzzi LA: Polypoidal choroidal vasculopathy. Ophthalmol Clin North Am 2002; 15: 537–554.
33.
Heier JS, et al: Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 2016; 123: 2376–2385.
34.
Boyer DS, Nguyen QD, Brown DM, et al; RIDE and RISE Research Group: Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology 2015; 122: 2504–2513.
35.
Regillo CD, Busbee BG, Ho AC, et al: Baseline predictors of 12-month treatment response to ranibizumab in patients with wet age-related macular degeneration. Am J Ophthalmology 2015; 160: 1014–1023.
36.
Chung SE, Kang SW, Lee JH, et al: Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 2011; 118: 840–845.
37.
Adamis AP, Shima DT: The role of vascular endothelial growth factor in ocular health and disease. Retina 2005; 25: 111–118.
38.
Marneros AG, Fan J, Yokoyama Y, et al: Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005; 167: 1451–1459.
39.
Nishijima K, Nh YS, Zhong L, et al: Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171: 53–67.
40.
Rahman W, Chen FK, Yeoh J, et al: Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients. Graefes Arch Clin Exp Ophthalmol 2013; 251: 1483–1488.
41.
Chong V: Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye 2016; 30: 270–286.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.